Amgen to offer Repatha at 60% discount to U.S. consumers

Core Insights - Amgen has launched its cholesterol medication, Repatha, directly to consumers in the U.S. at a reduced cash price [2] - This initiative is part of a broader response from pharmaceutical companies to political pressure [2] Company Actions - The launch of Repatha directly to consumers indicates a shift in Amgen's marketing strategy [2] - The reduced cash price aims to make the medication more accessible to patients [2] Industry Context - The move reflects a trend among pharmaceutical companies to address public and political concerns regarding drug pricing [2] - This action may influence competitive dynamics within the cholesterol medication market [2]